

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Molnupiravir in early SARS-CoV-2 infection, AI applications in COVID-19 clinical response, cardiovascular disease after COVID-19 infection

Peer reviewed journals featured:

- Randomised clinical trials of:
 - Molnupiravir vs placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection [here](#) and associated commentary [here](#)
 - Ivermectin vs placebo on time to sustained recovery in mild to moderate COVID-19 [here](#)
 - Favipiravir in early symptomatic COVID-19 [here](#)
 - Spikevax (Moderna) vaccine in children 6 months to 5 years of age [here](#)
- A narrative review on artificial intelligence applications used in the COVID-19 clinical response [here](#)
- Observational studies on:
 - Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank [here](#) and associated editorial [here](#)
 - Protection against Omicron from vaccination and previous infection in US prisons [here](#)
 - Monovalent mRNA vaccine effectiveness against COVID-19–associated hospitalisation in immunocompetent US adults during Omicron outbreak [here](#)
 - SARS-CoV-2 co-infections during the Omicron outbreak in France [here](#)
 - The Global Health Security Index (GHSI), country preparedness and mortality [here](#)
 - Severity of SARS-CoV-2 infection and priming of vaccine-induced immunity [here](#)
 - Vaccine protection and the risk of infection with Omicron BA.5 in Denmark [here](#)
 - Long-COVID post-viral chronic fatigue association with oxidative damage, lowered antioxidant defences and inflammation [here](#)
 - Vitamin D treatment in COVID-19 patients [here](#)
- Commentary on:
 - COVID-19 and the amplification of cardiovascular risk by psychological distress [here](#)
 - What next for COVID-19 vaccines? [here](#)
 - What COVID-19 has taught the world about ethics [here](#)
 - A ‘One Health’ surveillance approach for zoonotic pathogens [here](#)

Letters and correspondence discussed:

- Association between life expectancy at 60 years before COVID-19 and excess mortality [here](#)

Pre-peer review articles featured:

- Characterising and predicting long COVID in a large US academic medical centre [here](#)
- Global landscape of the host response to SARS-CoV-2 variants [here](#)
- Immunogenicity of the BA.5 Bivalent mRNA vaccine boosters [here](#)
- Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against Delta & Omicron [here](#)
- Distinct neutralising antibody escape of Omicron subvariants [here](#)
- Association of viral variant and vaccination status with long COVID symptoms [here](#)
- Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot [here](#)
- Vaccine- and BTI-elicited pre-Omicron immunity neutralisation of Omicron sublineages [here](#)
- Development of criteria for cognitive dysfunction in post-COVID syndrome [here](#)

Guidance and reports

- The World Health Organization published its weekly epidemiological report on COVID-19 [here](#)
- Australian Technical Advisory Group on Immunisation (ATAGI) recommendation for a booster dose of the paediatric Pfizer COVID-19 vaccine in children aged 5 to 11 years [here](#)
- The US department of Veterans Affairs (VA) published a guidebook on long COVID [here](#)

News and blogs

- Vitamin D supplements don't reduce COVID-19 risk [here](#)
- COVID-19 research is free to access - but for how long? [here](#)
- The FDA urged to publish follow-up studies on COVID-19 vaccine safety signals [here](#)
- Communication innovation in the COVID-19 era [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).